CORONAVIRUS INFO PROVIDED BY DR. JIM HARRIS – 04/05/2021
COVID VACCINE AVAILABLE ON WEDNESDAY IN MARSHALL
WEEKLY UPDATE OF HUBS AND INJECTION SITES IN AREA:
FROM THE NYT TODAY:
(J. Harris: Quick read, Variants all listed.)
GOOD NEWS HOPKINS CITATIONS;
1. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in[PFIZER AND MODERNA] Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021 (CDC MMWR) Prospective cohorts of 3,950 health care personnel, first responders, and other essential and frontline workers completed weekly SARS-CoV-2 testing for 13 consecutive weeks. Under real-world conditions, mRNA vaccine effectiveness of full immunization (≥14 days after second dose) was 90% against SARS-CoV-2 infections regardless of symptom status; vaccine effectiveness of partial immunization (≥14 days after first dose but before second dose) was 80%.
2. Side Effect Worry Grows for AstraZeneca Vaccine (Science) It’s been one step forward, two back for AstraZeneca’s COVID-19 vaccine. Even as the company rebutted criticism of its efficacy claims last week, a bigger problem loomed for the vaccine and the many millions depending on it. Evidence continues to accumulate that an unusual clotting disorder seen in dozens of European recipients is a real, albeit rare, side effect. A preprint has detailed a proposed mechanism, and multiple scientific groups have said the worry is legitimate and must be seriously weighed against the vaccine’s COVID-19 protection.
3. Mask Mandates, On-Premises Dining, and COVID-19 (JAMA) Evidence-based prevention strategies can reduce the transmission of SARS-CoV-2, the virus that causes COVID-19. Consistent and correct use of masks can prevent SARS-CoV-2 transmission, which predominantly occurs through inhalation and other exposure to respiratory droplets from infected persons. Mask use is particularly important because presymptomatic and asymptomatic spread is responsible for nearly 60% of COVID-19 cases.
(J. Harris: Keep using your masks in dangerous locals and around potential carriers).
4. Pfizer and BionTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study (Pfizer) Pfizer Inc. and BioNTech SE announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pivotal Phase 3 study through March 13, 2021, showing the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, was 91.3% effective against COVID-19, measured seven days through up to six months after the second dose. The vaccine was 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention (CDC), and 95.3% effective against severe COVID-19 as defined by the U.S. Food and Drug Administration (FDA). Safety data from the Phase 3 study has also been collected from more than 12,000 vaccinated participants who have a follow-up time of at least six months after the second dose, demonstrating a favorable safety and tolerability profile.
LAST BUT NOT LEASED:
(Thank you David Collins)
Save the whales. Collect the whole set.
On the other hand, you have different fingers.
GIVE US YOUR FEEDBACK. CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.